ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases, today announced the appointment of Ryan Zeidan, Ph.D., as Senior Vice President, Development. Prior to joining Millendo, Dr. Zeidan served as executive director, global project leader, at Celgene. Additionally, the Company promoted Jeffery Brinza, J.D., to Chief Administrative Officer and General Counsel; Andrew Spencer, Ph.D., to Senior Vice President, Preclinical Research & Development and Thomas Hoover to Senior Vice President, Corporate Strategy.
“We are pleased to welcome Ryan to Millendo Therapeutics. He brings a wealth of industry experience, as he managed the development of late-stage assets and was instrumental in the decision making for key strategic and operational activities at several biopharmaceutical companies,” said Julia C. Owens, Ph.D., President and Chief Executive Officer of Millendo. “We look forward to his guidance and expertise as we continue development of our clinical pipeline for orphan endocrine diseases.”
“I’m delighted to join Millendo at a time when the company is well positioned in an area where very little innovation has been seen,” commented Dr. Zeidan. “I am eager to utilize my background in pharmaceutical strategy and drug development to collaborate with my colleagues at Millendo to advance innovative product candidates for orphan endocrine diseases and hopefully to bring needed therapies to patients.”
Dr. Zeidan’s in-depth industry knowledge spans a number of therapeutic areas and modalities. Most recently at Celgene, he oversaw the development of two late-stage oncology assets in a variety of tumor types, including advancing both assets to Phase 3 registration studies. Prior to Celgene, Dr. Zeidan was executive director, global strategy and operations, at Novartis Oncology, where he supported the company in business-critical activities, including developing the five-year strategic plan and investor relations matters. Dr. Zeidan also worked at the Boston Consulting Group, where he focused on pharmaceutical and biotech strategy, and at Calando Pharmaceuticals, a biotech start-up, where he was one of the key scientific contributors.
Dr. Zeidan holds a Ph.D. in chemistry and chemical engineering from the California Institute of Technology, and bachelor’s degrees in chemistry and chemical engineering from the Massachusetts Institute of Technology.
About Millendo Therapeutics, Inc.
Millendo Therapeutics is focused on developing novel treatments for orphan endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing’s syndrome. www.millendo.com